News & Events

Weekly Media Tip Sheet

FDA News & Notes – Week of May 22, 2017

Science, public health, and regulatory highlights from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as of May 15, 2017. Times listed are local time.

FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations.

Meetings, Workshops and Congressional Testimony:

Wednesday, 5/31 – Thursday, 6/1 — The FDA is holding a 2017 FDA Science Forum that will highlight cutting-edge FDA-generated science. The forum, keynoted by Scott Gottlieb, M.D., Commissioner of Food and Drugs will include updates on the FDA’s work in 3D printing, biomarkers, medical countermeasure efforts, nanotechnology and more. It will be held on May 31, from 8:30 a.m. to 4:30 p.m. and on June 1, from 9:15 a.m. to 4 p.m. on the FDA’s White Oak Campus, Building 31, Great Room, Silver Spring, Maryland.
Press Office Contacts: Tara Goodin, 240-402-3157, tara.goodin@fda.hhs.gov and Lauren Smith Dyer, 301-348-1888, lauren.smith2@fda.hhs.gov

Tuesday, 5/23 — The House Energy and Commerce Subcommittee on Oversight and Investigations will hold a hearing at 10 a.m. on U.S. Public Health Response to the Zika Virus: Continuing Challenges. Luciana Borio, M.D., FDA’s Acting Chief Scientist, is scheduled to testify.
Press Office Contact: Tara Goodin, 240-402-3157, tara.goodin@fda.hhs.gov

Wednesday, 5/24 – Thursday, 5/25 — The Oncologic Drugs Advisory Committee will meet to discuss two pending new drug applications and one pending biologics license application. The meeting will be held on May 24, from 8 a.m. to 5 p.m. and on May 25, from 8 a.m. to 1:30 p.m. on the FDA’s White Oak Campus, Building 31, Great Room, Silver Spring, Maryland.
Press Office Contact: Angela Stark, 301-796-0397, angela.stark@fda.hhs.gov

Thursday, 5/25 — The House Appropriations Committee’s Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Subcommittee will hold a Budget Hearing at 10 a.m. Scott Gottlieb, M.D., Commissioner of Food and Drugs, is scheduled to testify.
Press Office Contacts: Jennifer Rodriguez, 301-796-8232, jennifer.rodriguez@fda.hhs.gov and Michael Felberbaum, 240-402-9548, michael.felberbaum@fda.hhs.gov

Did You Know?

The FDA’s Office of Health and Constituent Affairs issues a biweekly update for health professionals that includes announcements, opportunities for comment, product approvals and clearances, product safety, upcoming meetings, and additional resources. The updates can be viewed here.

In Case You Missed It:

Thursday, 5/18 — FDA Voice Blog: ‘Radiating Shoe Sales’. Since the discovery of X-rays in the late 19th century, the technology has enhanced health care in a variety of ways. Like many cutting-edge scientific developments, however, it also has inspired uses of uncertain therapeutic value. That was the case with the shoe-fitting fluoroscope, the subject of the latest episode of FDA’s history video series.
Press Office Contact: FDA Office of Media Affairs, 301-796-4540, fdaoma@fda.hhs.gov

Wednesday, 5/17 — News Release: FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis. The FDA expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug can now treat, expanding the indication from the treatment of 10 mutations, to 33. The agency based its decision, in part, on the results of laboratory testing, which it used in conjunction with evidence from earlier human clinical trials. The approach provides a pathway for adding additional, rare mutations of the disease, based on laboratory data.
Press Office Contact: Theresa Eisenman, 301-796-2969, theresa.eisenman@fda.hhs.gov

Wednesday, 5/17 — News Release: FDA warns Americans about risk of inaccurate results from certain lead tests. The FDA and Centers for Disease Control and Prevention are warning Americans that certain lead tests manufactured by Magellan Diagnostics may provide inaccurate results for some children and adults in the United States. The CDC recommends that parents of children younger than six years (72 months) of age, and currently pregnant women and nursing mothers who have been tested for lead exposure consult a health care professional about whether they should be retested.
Press Office Contact: Tara Goodin, 240-402-3157, tara.goodin@fda.hhs.gov

Tuesday, 5/16 — FDA Voice Blog: Reducing Preventable Harm from Medications: Too Big for FDA to Do Alone. Sometimes a drug can be used exactly as the FDA approved it, taken just the way a doctor prescribed it, and a patient can still experience adverse events. When it comes to drugs, not all risks are known – even after approval.
Press Office Contact: FDA Office of Media Affairs, 301-796-4540, fdaoma@fda.hhs.gov

Tuesday, 5/16 — Consumer Health Information: How to Safely Use Glucose Meters and Test Strips for Diabetes. Using a glucose meter to check and monitor blood sugar is a daily part of life for millions of Americans with diabetes. Press Office Contact: FDA Office of Media Affairs, 301-796-4540, fdaoma@fda.hhs.gov

FDA Office of Media Affairs Contact Information:

Media Inquiries: FDA Office of Media Affairs, 301-796-4540, fdaoma@fda.hhs.gov
List of FDA Press Officers and beats

More Resources:

Read our Blog: FDA Voice
FDA Photos disclaimer icon (Flickr)
Consumer Health Information
Scientific Publications by FDA Staff

Page Last Updated: 05/22/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English